Identification of microRNA 885-5p as a novel regulator of tumor metastasis by targeting CPEB2 in colorectal cancer by Wan, TMH et al.
Title Identification of microRNA 885-5p as a novel regulator of tumormetastasis by targeting CPEB2 in colorectal cancer
Author(s)
Lam, CSC; Ng, L; Chow, KM; Wan, TMH; Yau, S; Cheng, SM;
Wong, KM; Man, HW; Lo, OSH; Foo, CC; Poon, TCJ; Pang, RWC;
Law, WL
Citation Oncotarget, 2017, v. 8 n. 16, p. 26858-26870
Issued Date 2017
URL http://hdl.handle.net/10722/243826
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Oncotarget26858www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 16), pp: 26858-26870
Identification of microRNA 885-5p as a novel regulator of tumor 
metastasis by targeting CPEB2 in colorectal cancer
Colin Siu-Chi Lam1, Lui Ng1, Ariel Ka-Man Chow1,2, Timothy Ming-Hun Wan1, 
Simon Yau1, Nathan Shiu-Man Cheng1, Sunny Kit-Man Wong1, Johnny Hon-Wai 
Man1, Oswens Siu-Hung Lo1, Dominic Chi-Chung Foo1, Jensen Tung-Chung Poon1, 
Roberta Wen-Chi Pang1,2, Wai-Lun Law1,2
1Division of Colorectal Surgery, Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
2Centre for Cancer Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
Correspondence to: Roberta Wen-Chi Pang, email: robertap@hku.hk 
Lui Ng, email: luing@hku.hk
Keywords: CRC, liver metastasis, miR-885-5p, EMT, CPEB2
Received: August 16, 2016    Accepted: February 20, 2017    Published: March 02, 2017
Copyright: Lam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Colorectal cancer is the third most common cancer in the world and liver is the 
most frequent site of distant metastasis with poor prognosis. The aim of this study is 
to investigate microRNAs leading to liver metastasis. We applied microarray analysis 
and quantitative PCR to identify and validate dysregulated miRNAs in liver metastases 
when compared to primary CRCs. Functional significance and the underlying molecular 
mechanism of selected miRNA was demonstrated by a series of in vitro and in vivo 
assays. Our microarray analysis and subsequent quantitative PCR validation revealed 
that miR-885-5p was strongly up-regulated in liver metastases and in CRC cell-lines 
derived from distant metastases. Overexpression of miR-885-5p significantly induced 
cell migration, cell invasion, formation of stress fibre in vitro and development of 
liver and lung metastases in vivo. MiR-885-5p induced metastatic potential of CRC 
by repressing cytoplasmic polyadenylation element binding protein 2 transcription 
through directly binding to two binding sites on its 3′ untranslated region, and 
consequently led to up-regulation of TWIST1 and hence epithelial-mesenchymal 
transition. Our findings demonstrated the overexpression of miR-885-5p in liver 
metastasis and its roles in inducing CRC metastasis, potentiating development of 
miR-885-5p inhibitor to treat advanced CRC in the future.
INTRODUCTION
Colorectal cancer (CRC) is third most common 
malignancy and the third leading cause of cancer death 
in the United States and Hong Kong [1]. The patients 
with metastasis have a higher mortality rate than primary 
tumor development alone [2]. Liver is the most common 
site of distant metastasis with poor prognosis. Recently, 
microRNAs (miRNAs) have been identified as important 
molecules in regulating protein expression for metastasis 
[3, 4]. Understanding the biological mechanism of 
miRNAs in regulating liver metastasis is beneficial for 
developing new therapies. 
Metastasis formation is a complex multi-step 
process which is regulated by different signaling pathways 
and cell adhesion molecules (CAMs) [5, 6]. Epithelial-
mesenchymal transition (EMT), which is characterized 
by the cell reprogramming and transition from epithelial 
phenotype to mesenchymal phenotype, is a pivotal process 
that affects the tumor cell metastasis by altering cell-cell 
contact and cell-extracellular matrix (ECM) interactions 
[7, 8]. Tumors derived from epithelial cells can become 
more motile and invasive by acquiring characteristics of 
mesenchymal cells [9]. E-cadherin, which is expressed 
in epithelial cells and promotes cell-cell adhesion, is one 
of the decreased epithelial markers during EMT while 
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N-cadherin, Vimentin and Snail are increased mesenchymal 
markers [10]. Down-regulation of E-cadherin is mediated 
by transcription factors such as Snail and Slug, so up-
regulation of Snail has also been implicated as an EMT 
marker for metastatic cancers [11, 12].
A recent study demonstrated the critical role for 
miRNAs in EMT, a phenotypic change undergone by 
altered gene expression patterns that is theorized to have 
central roles in metastatic progression [13]. MiRNAs are 
a class of small (~22-nucleotide) non-coding RNAs that 
play a critical role in cellular proliferation, angiogenesis, 
differentiation and apoptosis by regulating gene expression 
via either specific post-translational repression or mRNA 
cleavage targeting [14, 15]. Regulation of miRNAs 
contributes to the etiology and process of oncogenesis 
through targeting of oncogenes or tumor suppresser 
genes [16–18]. Thus, miRNAs may be used as potential 
biomarkers for cancer diagnosis and prognosis [19]. 
Rho-GTPase family, RhoA, ROCK (Rho-associated 
coiled coil-containing protein kinase) and cdc42, participate 
in tumor cell invasion and migration through modulating 
the organization of stress fibers and focal adhesions 
[20]. MiRNAs are important for tissue morphogenesis 
by regulating cytoskeletal remodelling and phenotypic 
switching [21]. Besides, cell extravasation through the 
endothelium is an important event for tumor metastasis 
[6]. TWIST1 is a basic helix-loop-helix transcription factor 
which contributes to metastasis in many human cancers 
through promoting EMT pathway [22, 23]. Cytoplasmic 
polyadenylation was a mechanism that regulates the 
expression of gene by controlling poly(A) tail length 
in mammalian cells [24]. Cytoplasmic polyadenylation 
element binding protein (CPEB), which is the mediator 
of cytoplasmic polyadenylation, binds to the cytoplasmic 
polyadenylation element (CPE) in the 3′UTR of mRNA 
[25]. TWIST1 expression was regulated by cytoplasmic 
polyadenylation element binding protein 2 (CPEB2) post-
transcriptionally in CPE-dependent manner [26].
Since tumor cells have differential miRNA 
expression, it is critical to understand the mechanism 
behind this which may be beneficial for treatment [27, 28]. 
Thus, the difference between primary colon cancer and 
liver metastasis was investigated in this study to identify the 
novel factors that participate in liver metastasis for CRC.
RESULTS
miR-885-5p was significantly up-regulated in 
liver metastasis and metastatic CRC cell lines
To identify miRNAs associated with liver metastasis, 
we performed TaqMan® Low Density Array Human 
MicroRNA Panel with 754 human unique miRNAs (Sanger 
miRBase v16) to investigate the miRNA expression profiles 
of five human primary CRCs and five liver metastasis 
tumors. Among the miRNAs screened, miR-885-5p was 
highly up-regulated (~28.5-fold change, P = 0.036) in 
liver metastasis tumors when compared with primary 
CRCs (Supplementary Table 1). To confirm the microarray 
findings, qPCR was used to detect miR-885-5p level in a 
further 104 primary CRC and 39 liver metastasis tissues. As 
shown in Figure 1A, the median relative miR-885-5p level in 
liver metastasis samples (0.00284) was significantly higher 
than the level in primary CRCs (0.0000734; P < 0.001). 
More importantly, among these, there were two pairs of 
simultaneous CRC and liver metastasis samples from the 
same patients. Both of them showed much higher relative 
miR-885-5p level in their liver metastasis tumors (0.0111 
and 0.0629) when compared with the primary CRC 
(0.0000486 and 0.000180, respectively).
We also determined the expression of miR-885-5p 
among normal human intestinal epithelial cell line (CCD-
841-CoN), primary CRC cell-lines (HCT116, SW480, 
HT-29, HCT-15 and DLD-1) and cell lines derived 
from distant metastases of CRC (SW620 and Colo205) 
(Figure 1B). Comparing SW620 and SW480, which 
originated from the metastatic site and primary site of the 
same patient, respectively, miR-885-5p level was around 
8-fold higher in SW620. The expression level of miR-
885-5p was significantly higher in grouped CRC cell-
lines derived from metastatic site when compared with the 
grouped primary CRC cell-lines (P = 0.003; Figure 1C). 
For downstream functional experiments, primary CRC 
cell-lines HCT116 and DLD1 which expressed relatively 
lower level of miR-885-5p were used in miR-885-5p 
overexpression experiments. On the other hand, SW620 
and Colo205 which expressed higher level of miR-885-5p 
were used in miR-885-5p repression experiments.
miR-885-5p expression induced CRC cell 
migration and invasion through activation 
of epithelial-mesenchymal transition (EMT) 
pathway
To examine whether miR-885-5p functionally 
contributed to enhanced metastatic potential of CRC 
cells, miR-885-5p was ectopically expressed or repressed 
in CRC cell lines and the effect on the migratory capacities 
(invasion and migration) was studied (Figure 2A). 
HCT116 and DLD1 cell-lines were transiently transfected 
with control or miR-885-5p precursors. miR-885-5p 
overexpressing cells migrated at a higher rate than negative 
control as shown by the wound-healing assays (Figure 2B). 
Figure 2B lower panel shows the quantified distance 
between the migrated cells at different time points. Similar 
results were observed when transfectants were subjected 
to migration chamber assays in vitro (Figure 2C). miR-
885-5p overexpressing cells have greater migratory 
capacity (~2 fold) than the transfected negative control. 
On the other hand, high miR-885-5p expressing cells 
Colo205 were transiently transfected with miR-885-5p 
inhibitor (Anti-miR) to study the effect of miR-885-5p 
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repression. Migration rate of cells with miR-885-5p 
inhibition was significantly impaired in comparison to the 
control which was shown by the migration chamber assays 
(Figure 2C).
We also demonstrated the causative role of miR-
885-5p expression and invasive phenotypes of CRC cells. 
Overexpression of miR-885-5p substantially increased 
the invasive properties of CRC cells as shown from the 
transwell matrigel™ invasion chambers assay (Figure 2D). 
The cell invasion result was quantified with relative fold 
change to the mimic control. Invasion assay demonstrated 
that miR-885-5p overexpressed cells showed around five 
times more number of invaded cells when compared with 
the control transfected cells. On the other hand, miR-885-5p 
inhibition in Colo205 cells by transient transfection of 
anti-miR miR-885-5p reduced their invasive capacities 
when compared with negative control in the invasion 
chamber assay (Figure 2D).
We investigated whether ectopic expression of miR-
885-5p alter the EMT pathway of CRC cells, which is 
an important process for inititation of cancer metastasis. 
Western blotting revealed that overexpression of miR-885-
5p led to repression of E-cadherin and concomitant up-
regulation of N-cadherin and Snail (Figure 3). Moreover, 
Vimentin expression level was increased with time in Pre-
miR transfectants. On the other hand, knockdown of miR-
885-5p led to enhanced expression of E-cadherin, as well 
as a concordant decrease in Snail and Vimentin expression 
in Colo 205 and SW620 respectively. These results 
suggested that miR-885-5p induced metastatic capacity of 
CRC cells through activating the EMT pathway.
Expression of miR-885-5p enhanced stress fiber 
formation through cytoskeleton rearrangement
We analysed the effect of miR-885-5p on actin stress 
fiber formation. As shown in Figure 4A, co-staining showed 
the formation of cell protrusion (indicated by the arrows) 
was enhanced in miR-885-5p Pre-miR transfectants as 
compared with actin cortical ring which was observed 
in control transfectants. Our results also showed that the 
stress fiber formation of overexpressing miR-885-5p 
transfectants was increased to ~80% as compared with 
~20% of the negative control transfectants. Since the cell 
elasticity is directly inﬂuenced by the intracellular actin, 
over-expressing miR-885-5p clearly demonstrated higher 
quantities of actin stress fibers formation when compared 
with the cortical ring in negative control.
De-regulation of Rho family small GTPases 
have been widely reported to be accounted for cell 
protrusions and actin stress fiber formation in invasive 
cancer cells [29]. The effect of miR-885-5p expression 
on levels of Rho family small GTPases, RhoA, RhoC, 
ROCK1 and cdc42, was detected by western blotting 
(Figure 4B). Higher RhoA and ROCK1 expression was 
exhibited in Pre-miR transfectants. In addition, nuclear 
and cytooplasmic expression of RhoC was induced by 
miR-885-5p overexpression. In contrast, the expression 
of Rho family small GTPases were inhibited in anti-miR 
transfectants. These results suggested that miR-885-5p 
induced the actin filaments reorganization through up-
regulation of the Rho family small GTPases, leading to 
the formation of motility structures at the leading edge 
of cells.
miR-885-5p down-regulated CPEB2 by directly 
binding to CPEB2 3′UTR
We hypothesized that miR-885-5p activated EMT 
through its potential target gene CPEB2, which is one 
of the negative regulators of TWIST1 expression in a 
sequence-specific manner [26]. Our results showed that 
CPEB2 was significantly down-regulated in the cells 
overexpressing miR-885-5p and was conversely up-
Figure 1: High miR-885-5p level is associated with distant metastasis in CRC patient samples and cell-lines. 
(A) Expression of miR-885-5p in 104 CRC and 39 liver metastasis (LM) specimens was detected by qRT-PCR. The relative miR-885-5p 
level in liver metastases (median = 0.00284) was significantly higher than that in CRC (median: 0.0000734; P < 0.001 by Mann-Whitney 
Rank Sum test). (B) Expression of miR-885-5p in normal colon cell-line CCD-841-CoN (CCD841), primary CRC cell-lines (DLD1, 
HT29, LoVo, HCT116, HCT15 and SW480) and CRC cell-lines derived from distant metastases (SW620 and Colo205) was detected by 
qRT-PCR. (C) Comparison of miR-885-5p level between grouped primary CRC cell-lines and grouped CRC cell-lines derived from distant 
metastases. The relative expression of miR-885-5p was calculated by the 2−ΔCt method: 2-(Ct of miR-885-5p – Ct of RNU6). Data shown is the mean 
value (± SEM) of triplicates from three independent experiments. 
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Figure 2: miR-885-5p enhances CRC cells invasive and migratory capacity. (A) The relative expression of miR-885-5p 
in miR-885-5p overexpressed or control transfected cells (HCT116 and DLD1) and miR-885-5p repressed or control transfected cells 
(Colo205 and SW620). (B) Wound healing experiment was performed using HCT116 and DLD1 cells transfected with either negative 
control or Pre-miR miR-885-5p. Representative images of wound were at time 0 hr and 24 hr after monolayer wounding were shown 
(upper panel). The distance of cell migration was measured every 12 hours and relative distance % was calculated by the formula (initial 
wound distance –wound distance at time point)/ intial wound distance × 100%. The distance of cell migration was higher in cells transfected 
with miR-885-5p in both HCT116 and DLD1 cell-lines (lower panel; ***P < 0.001 by student’s t-test). Data is expressed as mean values 
(± SEM) of triplicate measurements from three independent experiments. (C and D) Transwell cell migration (C) and invasion assays 
(D) were performed using HCT116 cells transfected with either control or miR-885-5p (upper panel) and Colo205 cells transfected with 
either negative control or anti-miR-885-5p inhibitor (lower panel). Cells migrated or invaded were stained with 0.2% crystal violet and the 
number was counted under microscope. The number of cells migrated or invaded was significantly higher in HCT116 cells transfected with 
miR-885-5p than that with control, and significantly lower in Colo205 cells transfected with anti-miR-885-5p inhibitor than with negative 
control (*P < 0.05, student’s t-test). Data is expressed as mean values (± SEM) of five measurements in three independent experiments.
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regulated in anti-miR transfectants, whereas TWIST1 was 
conversely expressed with CPEB2 (Figure 5A).
Dual luciferase reporter assays were performed 
in HCT116 cells to test whether miR-885-5p directly 
target the CPEB2 3′-UTR. Reporter plasmids containing 
CDK2 or MCM5 3′-UTR binding sites were included as 
positive controls [30] (Figure 5B). Two potential target 
binding sites of miR-885-5p in CPEB2 3′-untranslated 
region, namely CPEB2-1 and CPEB2-2, were predicted 
by miRNA database (www.microrna.org) [31] (Figure 
5C). Two oligonucleotides containing the CPEC2-1 and 
CPEB2-2 sequences were cloned into pMIR reporter 
vector. In addition, reporter constructs containing mutated 
CPEC2-1 and CPEB2-2 sequences were prepared (Figure 
5D). The relative fireﬂy luciferase activities of positive 
controls were inhibited by around 25% in the presence 
of miR-885-5p pre-miR co-transfectants (Figure 5E), 
indicating our system demonstrated the regulation of 
miR-885-5p on its target genes. Relative fireﬂy luciferase 
activities of reporter plasmids containing CPEB2-1 or 
CPEB2-2 3′-UTR binding sites were inhibited by 32–38% 
in the presence of miR-885-5p Pre-miR but not mimic 
control nor plasmid only. More importantly, luciferase 
activity was not affected by miR-885-5p co-transfection 
when the 3′UTR sequences of the CPEB2-1 and CPEB2-2 
reporter plasmids were mutated. These findings showed 
that miR-885-5p directly targeted the two predicted miR-
885-5p binding sites in the CPEB2 3′UTR. 
Figure 3: Effect of miR-885-5p on epithelial-mesenchymal transition proteins. The effects of miR-885-5p overexpression 
or inhibition on protein level of epithelial mesenchymal transition pathway were detected by western blotting. Upper panel: miR-885-5p 
overexpression in HCT116 cells induced N-cadherin and Snail expression and repressed E-cadherin level. The expression of Vimentin at 
different time points in HCT116 cells was determined in HCT116 cells. Vimentin was weakly expressed in mimic control transfected cells 
after 96 hours whereas its expression was strongly induced in miR-885-5p overexpressed cells after 48 hours and further induced after 72 
and 96 hours. Lower panel: miR-885-5p repression in Colo 205 and SW620 cells induced E-cadherin level whereas repressed Snail in Colo 
205 cells and Vimentin in SW620 cells. Total β-actin was used as loading control. Images shown were representative results from at least 
three independent experiments.
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Role of miR-885-5p in the development of 
metastasis of CRC in vivo
To explore the role of miR-885-5p in tumor 
metastasis in vivo, luciferase-labelled HCT116 cell-line was 
transduced with empty lentivector (control) or precursor 
lenti-miR-885-5p (precursor miR-885-5p). 1 × 106 cells 
of each stable clone were orthotopically injected into the 
cecal wall of 9 NOD-SCID mice and allowed to growth 
for 6 weeks. After 6 weeks, the mice were sacrificed and 
presence of tumor in cecum and metastatic tumor in liver 
and lung were detected by capturing the luciferase signal. 
We found that stable transfection of precursor miR-885-5p 
in HCT116 cells induced their metastatic capacity. Out of 
the 9 mice, 6 and 5 developed metastatic lesions in the liver 
and lung, respectively (Figure 6), whereas only 2 of control 
mice developed liver and lung metastases.
DISCUSSION
Development of distant metastasis is the major cause 
of high mortality rate of CRC patients [32]. It is necessary 
to identify factors that confer metastatic capacity to tumor 
cells in order to understand the molecular mechanism 
leading to cancer metastasis, and to develop therapeutic 
agents to inhibit such transformation. Many miRNAs 
were identified as metastasis promoter or suppressor and 
thus provide us a new perspective on investigating the 
metastatic process [33, 34]. Therefore, this study aimed 
at identifying miRNAs responsible for CRC metastasis 
by comparing the miRNA profiles between primary CRCs 
and liver metastases.
Our miRNA microarray results showed that miR-
885-5p was significantly overexpressed in liver metastasis 
when compared with primary CRC. This finding was also 
Figure 4: Effect of miR-885-5p on formation of cell protrusions. (A) Upper panel: HCT 116 and DLD-1 cells transfected with 
negative control or miR-885-5p were stained with phalloidin and DAPI. Representative micrographs showing formation of cell protrusions 
(indicated by arrows) and signals from F-actin (green) and nucleus (blue). Scale bar: 50 µm. Lower panel: Bar graph showing percentage 
of cells with cell protrusion formation in five random area. Data is expressed as the mean (± SEM) of three independent experiments. 
(***P < 0.001, student’s t-test). (B) Analysis of endogenous levels of Rho-GTPase families by immunoblotting in CRC cell lines transiently 
transfected with pre-miR-885-5p, negative control or anti-miR-885-5p for 48 hours. Total β-actin was used as a loading control.
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confirmed by quantitative PCR in another cohort of liver 
metastasis and primary CRC samples. Moreover, comparing 
the miR-885-5p level in two paired primary CRCs and 
liver metastases samples, both of them demonstrated 
much higher level in their liver metastases. These results 
clearly demonstrated that high miR-885-5p was associated 
with liver metastasis. During this study was in progress, 
other research groups also reported upregulation of miR-
885-5p level in liver metastases when compared with the 
paired primary CRC [35, 36]. In Hur et al’s study, they 
further demonstrated serum miR-885-5p expression was 
statistically significantly associated with lymph node 
metastasis, distant metastasis, TNM stage, liver metastasis, 
and lymphatic invasion. On the other hand, tissue 
expression of miR-885-5p expression was not associated 
with clinico-pathological factors. In another recent rectal 
carcinoid tumor study, miR-885-5p was the most up-
regulated miRNA in the rectal carcinoid tumors with 
lymphovascular invasion compared with that in those 
without invasion, and high miR-885-5p expression was 
independently associated with lymphovascular invasion 
[37]. Since we and Vychytilova-Faltejskova et al’s study 
did not perform such correlation analysis, it is not known 
whether similar findings will be observed in our patient 
cohorts. However, our study may provide an explanation 
to such finding. Based on our functional experiments that 
high miR-885-5p CRC cells possessed higher potential to 
migrate and invade, we hypothesize the CRC cells with 
higher miR-885-5p level evade from the primary site and 
enter circulation system and spread to distant organ(s), 
hence its level in serum but not tissue correlated with 
metastatic features in Hur et al’s study. Moreover, similar 
to Hur et al and Vychytilova-Faltejskova et al’s studies, our 
miRNA profiles also demonstrated that miR-885-5p and 
Figure 5: Identification of CPEB2 as a target gene of miR-885-5p. (A) qPCR was applied to detect the mRNA level of CPEB2 
and TWIST1 in HCT116 and DLD1 cells overexpressed with control or miR-885-5p, as well as in Colo205 and SW620 cells transfected 
with negative control or anti-miR-885-5p inhibitor. Data is expressed as the mean (± SEM) of three independent experiments. (***P < 0.001, 
**P < 0.01, *P < 0.05, student’s t-test). (B) Reported binding sites of miR-885-5p on CDK2 and MCM5 gene which were used as positive 
control in our luciferase reporter experiments. (C) Two potential binding sites of miR-885-5p (CPEB2-1 and CPEB2-2) were predicted in the 
3′UTR region of CPEB2 gene. (D) Designs of CPEB2-1 and CPEB2-2 mutants for luciferase reporter assay. Upper case: Potential binding 
sites of miR-885-5p; Underline: mutated nucleotides. (E) HCT116 cells were transiently co-transfected with miRNA control or miR-885-5p 
and reporter construct containing miR-885-5p binding sites or mutants of CPEB2 (CPEB2-1 or CPEB2-2). CDK2 and MCM5 are included 
as positive controls. Fireﬂy luciferase values were normalized by Renilla activity, and results were expressed as the percentage of luciferase 
activity of each co-transfection with reference to the luciferase activity of the same reporter construct with miRNA negative control only. 
Data is expressed as the mean (±SEM) of three independent experiments. (***P < 0.001, **P < 0.01, *P < 0.05, student’s t-test).
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miR-122 were highly expressed in liver metastases when 
compared with the primary CRC samples (Supplementary 
Table 1). Since our downstream experiments suggested that 
miR-122 did not play a functional role in CRC metastasis 
(data not shown), hence this study focused on miR-885-5p.
Metastasis development is a multi-step complex 
process which is initiated by loss of cell-to-cell adhesion. 
During EMT, tumor cells lose cell-cell adherence and 
undergo a remarkable rearrangement of the cytoskeleton 
to facilitate cell motility and invasion into adjacent 
connective tissues [7, 9, 10, 38]. It is known that the loss 
of E-cadherin is essential in initiating EMT and cellular 
detachment, so that the cancer cells can metastasize to 
distant organs [10]. In the present study we found that 
up-regulation of miR-885-5p had a significant impact on 
EMT. Overexpression of miR-885-5p resulted in decreased 
E-cadherin expression level, together with elevated levels 
of N-cadherin; the expression of Vimentin, suggesting that 
the non-metastatic CRC cell lines were undergoing EMT 
process and became more invasive. Down-regulation of 
E-cadherin was accompanied with increased expression 
level of its transcription regulator Snail, which further 
demonstrated that miR-885-5p up-regulation enhances 
the metastatic properties of CRC through activation of 
the EMT pathway. Knockdown of miR-885-5p not only 
conversely resulted in enhanced E-cadherin expression 
Figure 6: miR-885-5p induces CRC metastasis in vivo. (A) Real-time RT-PCR was used to determine miR-885-5p expression level 
in luciferase-labelled HCT116 cell line stably transduced with empty lentivector (control) or precursor miR-885-5p. (B) The size of primary 
tumors developed from stable cells 6 weeks after orthotopically injected into the cecal wall of 9 mice per group. There was no significant 
difference in tumor size formed from control and miR-886-5p stable cells (P = 0.427). (C) The primary tumors, livers and lungs were 
excised and presence of tumor cells were detected by capturing the luciferase signal by the IVIS Imaging System. Primary tumors were 
detected in all mice injected with either control or precursor miR-885-5p stable cells. Liver and lung metastases were detected in only two 
mice of the control group, while 6 and 5 mice developed liver and lung metastases, respectively, in the miR-885-5p group.
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level but also showed the decreased levels of Snail and 
Vimentin in metastatic CRC cell lines, while inhibiting 
the cell motility and invasiveness. Thus, miR-885-5p 
probably targets regulator of EMT to enhance motility and 
invasiveness in CRC cells.
The migration ability increased upon the 
overexpression of miR-885-5p in wound healing and 
migration chamber assay, which was further demonstrated 
by stress fiber formation assay. High expression level of 
miR-885-5p increased stress fiber formation and finally, 
enhanced the cell migration. The role of Rho small GTP 
binding proteins in the regulation of actin cytoskeleton 
arrangement and cell migration has been well published 
[39]. Actin filaments are necessary for the maintenance 
of cytoskeleton networks, which regulate cell shape and 
cell motility. Although, the mechanisms for regulating 
N-cadherin expression in metastasis remain unclear, 
Bhowmick et al. showed that GTPase RhoA signaling was 
necessary for N-cadherin induction by TGFβ1 [40]. Our 
study demonstrated the overexpression of miR-885-5p in 
CRC cells stimulated the RhoA expression and formation 
of stress fiber without affecting the actin expression level. 
Inhibition of miR-885-5p in metastatic CRC cells conversely 
inhibited the expression of Rho small GTP binding proteins. 
For the first time, this study provided evidence supporting 
the role of miR-885-5p in the regulation of cytoskeleton 
through a Rho-GTPase signaling pathway. Rho-GTPase 
activity is determined by the amount of the GTP-binding, 
which is regulated by three sets of proteins, guanine 
exchange factors (GEFs), GTPase-activating proteins 
(GAPs) and guanine nucleotide-dissociation inhibitors 
(GDIs). Thus, miR-885-5p may also target members of 
GEFs, GAPs, or GDIs to increase GTP-bound Rho in miR-
885-5p overexpressing cells. Further study is essential to 
identify which Rho regulator is targeted by miR-885-5p 
that leads to Rho-GTPase activation.
More importantly, this study demonstrated miR-885-
5p activated EMT through targeting CPEB2, which is a 
negative regulator of TWIST1 [26]. TWIST1 is one of the 
regulators which promote EMT pathway in many cancers 
[22, 23]. We demonstrated that miR-885-5p overexpression 
resulted in CPEB2 repression, which in turn induced 
TWIST1 expression in CRC cell line; on the other hand, 
anti-miR knockdown of miR-885-5p induced CPEB2 
expression and repressed TWIST1 level. Furthermore, our 
data from luciferase reporter assays confirmed that miR-
885-5p directly reguated the transcription of CPEB2 by 
functionally targeting two binding sites (CPEB2-1 and 
CPEB2-2) in CPEB2 UTR region.
Indeed, miR-885-5p is shown to be highly expressed 
in the liver and is associated with acute liver injury [41–43]. 
Similar to their findings, our results also demonstrated 
much higher miR-885-5p level in liver metastases and 
adjacent normal liver specimens than in CRC samples. 
We compared the miR-885-5p level in matched-liver 
metastases and non-tumor liver from 4 patients. The 
average relative miR-885-5p expressions in liver 
metastases and non-tumor liver were 0.0120 and 0.157, 
respectively. Furthermore, we detected the expression of 
paired HCC and non-tumor liver from 2 HCC patients 
(average: 0.769 and 0.332, respectively). We noticed the 
expression of miR-885-5p was much higher in adjacent 
normal liver when compared with the liver metastases 
samples, and even higher in paired-HCC and non-tumor 
liver specimens. Therefore, to prevent the inﬂuence of 
liver cells on miR-885-5p expression in liver-metastasis 
specimens, frozen samples were macrodissected with 
cryostat at –20°C to remove surrounding healthy liver 
tissue and three sections of 30 μm were collected for 
RNA extraction. Similar macrodissection procedure was 
also performed prior to RNA extraction in another recent 
colorectal cancer study which showed higher miR-885-5p 
expression in liver metastases when compared with the 
primary colorectal cancer specimens [36], confirming 
the higher expression of miR-885-5p in liver metastases 
was not due to tissue difference. In addition, miR-885-5p 
showed a higher expression in CRC cell-lines derived 
from metastatic site [SW620 (lymph node) and Colo205 
(Ascites)], and our in vitro and in vivo experiment results 
which showed that miR-885-5p overexpression in CRC 
cell-lines induced migration, invasion and metastasis 
further indicated the high miR-885-5p level in liver 
metastases was due to the presence of miR-885-5p-high 
CRC cells which were more metastatic.
To conclude, we clearly showed in this study that 
miR-885-5p plays a crucial role in liver metastasis by 
enhancing cell motility, invasiveness, regulating EMT 
pathway through silencing its target gene CPEB2 which is 
a negative regulator of TWIST1. These findings, not only 
provide more information on molecular mechanism leading 
to CRC metastasis, but also potentiate the development of 
miR-885-5p inhibitor to treat advanced CRC.
MATERIALS AND METHODS
Patient samples and cell lines
Fresh randomized clinical tumor specimens were 
obtained from the Department of Surgery, Queen Mary 
Hospital, The University of Hong Kong between 2006 and 
2009. All specimens were ﬂash frozen in liquid nitrogen 
and stored at –80°C until use. The study was approved by 
the Institutional Review Board. Histological assessment 
was performed by two experienced pathologists. CCD-
841-CoN, Colo 205, DLD-1, HCT 116, HCT-15, HT-29, 
SW480 and SW620 cell lines (American Type Culture 
Collection, ATCC) were cultured in medium according to 
ATCC. 
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RNA extraction and real-time quantitative  
RT-PCR
Frozen samples were macrodissected with cryostat 
at –20°C to remove surrounding healthy tissue. Three 
sections of 30 μm were collected for RNA extraction. 
Total RNA that includes small RNAs from tissues and 
cells were isolated using mirVana™ miRNA Isolation 
Kit (Ambion, Austin, TX, USA) according to the 
manufacturer’s instructions. All RNA samples were 
classified as good quality and were frozen at −80°C until 
further experiments if the 260/280 ratio higher than 2. In 
RT reactions, total miRNA was reverse transcribed into 
cDNA with Megaplex™ Primers Pools (Life Technologies 
Co.) for 754 unique miRNA. RNU6 snRNA and RNU48 
were used on each experiment for endogenous control and 
an assay unrelated to mammalian species, ath-miR159a, 
providing a process control. Real-time qRT–PCR was 
performed using 7900HT (Life Technologies Co.). 
Experiments were performed in triplicate, independently. 
The relative expression of miR-885-5p was calculated by 
the 2−ΔCt method: 2-(Ct of miR-885-5p – Ct of RNU6).
Protein extraction and western blotting 
Cells were lysed in RIPA buffer (Cell Signaling 
Technology, Danvers, MA) containing 1 mmol/l 
phenylmethylsulfonyl ﬂuoride (PMSF) and 1X protease 
inhibitor cocktail (Cell Signaling Technology), the lysates 
were quantified using the BCA protein assay (Roche). 
Subcellular proteomes were isolated by compartment 
protein extraction kit (Millipore Co., Billerica, MA, 
USA). Primary antibodies used were against actin (Santa 
Cruz Biotechnology, Santa Cruz, USA), N-Cadherin, 
E-Cadherin, Snail, Vimentin, RhoA, RhoC, cdc42 and 
ROCK1 (Cell Signaling, Danvers, MA, USA). 
Wound-healing assay
Colorectal cell lines were seeded into 6-well plates 
at 1 × 105 per well. Conﬂuent monolayers were starved 
overnight and a single scratch wound was created 
by dragging a 1 ml plastic pipette tip across the well 
surface. Cells were washed with phosphate-buffered 
saline (PBS) twice and was assessed using an Olympus 
CKX41 microscope (Olympus, CenterValley, PA). Cell 
migration distance was measured using ImageJ software 
with different time points. The distance was calculated and 
expressed as a relative distance between times 0 and 48 hr.
Transwells migration and matrigel invasion 
assays
Transwells with 8-µm pore size filters covered 
with (BD biosciences) or without matrigel (Corning 
Incorporated, Corning, NY, USA) were inserted into 24-well 
plates for invasion or migration assay, respectively. 
Medium (500 μl) containing 10% FBS as chemo-attractant 
was added to the lower chamber, and 300 μl of a serum-
free cell suspension (5 × 104 cells) was placed in the 
upper chamber. The plates were incubated at 37°C with 
5% CO2 for 48h and cells that did not migrate or invade 
through the pores were removed by a cotton swab. Cells 
in the lower chamber were fixed in methanol and stained 
with 0.1% crystal violet. Number of invasive cells in five 
randomly selected fields from each chamber and were 
counted in each experiment. Experiments were performed 
independently at least three times.
Immunofluorescence microscopy
Colorectal cells were fixed with 4% formaldehyde 
in PBS for 15 min and permeabilized with 0.1% Triton 
X-100 in PBS for 10 min. After blocking with 5% BSA 
for 1 h, the cells were incubated with anti-phalloidin 
Fluorescein Isothiocyanate Labelled (Sigma) overnight 
at 4°C. Coverslips were mounted with ProLong® Gold 
anti-fade reagent (Life Technologies) containing nuclear 
stain 4′, 6-diamidino-2-phenylindole (DAPI) and then 
visualized using a Zeiss Axioplan 2 microscope (Carl 
Zeiss, Jena, Germany). Cells were scored as positive for 
intensive stress fibers when bundles of actin filaments 
were seen clearly emerging from the central portion of the 
cell. In all quantifications, only those cells presenting with 
free borders were considered, and at least 100 cells from 
randomly selected fields were evaluated.
Luciferase labelled cell line
HCT 116 cells were transfected with fireﬂy 
luciferase-expressing plasmid (Promega) and selected by 
puromycin. A single clone was picked out and grown in 
the medium containing 1 μg/ml puromycin.
Lentiviral vectors and transduction
The pCDH-CMV-MCS-EF1-copGFP lentivector 
with CMV promoter to introduce short hairpin lenti-miR 
microRNA precursors (Pre-miR) and anti-microRNA 
(miZIP) were obtained from System Biosciences (SBI, 
Mountain View, CA, USA). The pseudoviral particle 
producer 293TN cell line (SBI) was transiently co-
transfected with plasmid DNA and pPackH1 Packaging 
Plasmid Mix (SBI) using Lipofectamine™ 2000 (Life 
Technologies Co., Carlsbad, CA, USA). The virus-
containing supernatants were collected and filtered 48 h 
after transfection and then used to infect colorectal cell 
lines in the presence of 5 μg/ml polybrene (Sigma, USA). 
After infection, the cells were sorted by MoFlo™ XDP 
(Beckman Coulter, Brea, CA, USA) by green ﬂuorescent 
protein (GFP) signal in order to select out the stable gain-
of-function cells.
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Luciferase reporter assay
miRNA-3′-UTR binding sites were identified 
by microRNA.org. pMIR-REPORT™ System (Life 
Technologies Co.) was used for reporter assay according 
to manufacturer instructions and co-transfected with 
Renilla luciferase vectors, phRL-TK (Promega, 
Madison, WI, USA), as an internal transfection control. 
Reporter plasmids were created by cloning putative miR-
885-5p target sites in the CPEB2 3′-UTR into pMIR-
REPORTER vector downstream of the fireﬂy luciferase 
gene in pMIR-REPORTER vector. Westermann’s lab 
identified miR-885-5p target sites in the CDK2 and 
MCM5 were used as positive control with modifications 
of restriction enzyme: SpeI-3′UTR target site-MluI [30].
Cells were plated in 24-well plates, and 
transfected with 200ng of either pMIR empty, 
pMIR-CPEB2, pMIR-CDK2 or pMIR-MCM5 using 
Lipofectamine® 2000 (Life Technologies Co.), or 
miRNA mimics. After 24-h post transfection, cells were 
lysed in passive cell lysis buffer (Promega). Lysates 
were transferred into 96-well plates and processed 
using the Dual-Luciferase Reporter Assay System 
(Promega) according to the manufacturer instructions. 
The luminescence was measured in a FluorStar Optima 
Microplate Luminometer. Fireﬂy luciferase activity was 
normalized to Renilla luciferase activity. Transfections 
were done in triplicate and repeated in three individual 
experiments.
Animal experiments
Male 6- to 8-week-old NOD.CB17-Prkdcscid/J 
NOD/SCID mice (The Jackson Laboratory, Bar Harbor, 
Maine) were purchased from Laboratory Animal Unit. 
Colorectal HCT116 cells (1 × 106 cells) were suspended 
in 50 μl of serum-free medium per 50 μl Matrigel (BD 
Biosciences, Sparks, MD) and injected orthotopically 
into the cecal wall of NOD/SCID mice to determine 
tumor metastasis. All animal experiments were 
approved by Committee on the Use of Live Animals in 
Teaching and Research. Mice were sacrificed 6 weeks 
after injection and the primary tumor, liver and lung 
bioluminescence signal were detected by Xenogen in 
vivo imaging system 100 series (Caliper Life Sciences, 
Inc, Hopkinton, MA).
Statistical analysis
The results were performed in triplicate and were 
presented as mean ± SEM of at least three independent 
experiments. Different values among each group were 
analysed by using Student’s t-test or one-way ANOVA. 
Continuous data were expressed as median, and Mann-
Whitney U test was used to compare between groups. The 
χ2 test (or Fisher exact test where appropriate) was used for 
nominal variables. All statistical analyses were performed 
by SPSS 16 statistical software (SPSS, Chicago, IL). 
P < 0.05 was considered statistically significant. 
Abbreviations 
CRC, colorectal cancer; miRNA, microRNA, 
CPEB2, cytoplasmic polyadenylation element binding 
protein 2; EMT, epithelial-mesenchymal transition.
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